HDUP, MFLI, XPGH, CVM, SGTI, CYCC and DKAM are the Feb. 17th Daily Market Movers Digest Picks from OTCPicks.com.

Dallas- OTCPicks.com’s Daily OTC Stocks Newsletter presents a range of the hottest small cap, micro cap and penny stocks trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and micro cap traders to meet up and discuss their top stock picks.

Visit http://www.otcpicks.com/hotpicks.htm today to sign up for our Free Daily Email Newsletter and News Alerts.

HEADSUP ENTERTAINMENT INTERNATIONAL (OTC: HDUP)

"Up 9.09% in morning trading"

HeadsUp Entertainment International Inc. is a global media and entertainment company engaged in the creation of branded entertainment through the development, production and marketing of televised programming based on poker and other entertainment themes. For more information see the Company's websites www.headsupentertainment.com and www.canadianpokertour.tv.

MUSCLE FLEX INCORPORATED (OTC: MFLI)

Muscle Flex Inc. brings new products to market using direct response TV infomercials specializing in the health, fitness, wellness and hygiene sectors. As well, Muscle Flex Inc. develops and creates general television content for network and cable television distribution. Muscle Flex's corporate strategy is to develop new and innovative products for sale and distribution via its proprietary direct response marketing system and the creation of television media and shows for general network and cable broadcast.

XCELPLUS GLOBAL HOLDINGS INCORPORATED (OTC: XPGH)

Xcelplus Global Holdings, Inc., a development stage company, develops and produces federally compliant biomass based renewable fuels for the light, medium, and heavy industries. Its product lines include synthetic fuel oils, biomass release agent, and btu enhancer. The company holds various technologies and licenses them for manufacturing and distribution. Its technologies include digiflex, lubrilon, alternative energy centers, E85 flex lube centers, diesenol, glycoal, and glyclene. The company is headquartered in Dothan, Alabama.

CEL-SCI CORPORATION (AMEX: CVM)

"Up 21.37% in morning trading"

CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company is also developing CEL-1000, which is derived from a pre-clinical technology called ‘Ligand Epitope Antigen Presentation System’ to stimulate the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer; and CEL-2000 for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.

SHENGTAI PHAMRACEUTICALS (OTCBB: SGTI)

"Up 19.47% in morning trading"

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the holding company for Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of glucose products, which include pharmaceutical grade glucose used for medical purposes, and glucose and cornstarch products for the food and beverage industry and for industrial production in China.

CYCLACEL PHARMACEUTICALS INCORPORATED (NASDAQ: CYCC)

"Up 16.25% in morning trading"

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

DRINKS AMERICAS HOLDINGS LIMITED (OTCBB: DKAM)

"Up 15.00% in morning trading"

Drinks Americas develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned icon celebrities. Drinks Americas' portfolio of premium alcoholic beverages includes Trump Super Premium Vodka and Willie Nelson's Old Whiskey River Bourbon. The Company's non-alcoholic brands include the distribution of Paul Newman's Own Lightly Sparkling Fruit Juice Drinks and Flavored Waters. The company also has a partnership with Universal Music’s Interscope, Geffen, A&M Records to jointly develop and launch beverage products. Other products owned and distributed by Drinks Americas include award-winning Damiana Liqueur and Aguila Tequila from Mexico, Cohete Rum Guarana from Panama, and Rheingold Beer. Damiana, Old Whiskey River, Aguila Tequila and Cohete Rum are Gold and Silver Medal award winners respectively from the International Beverage Tasting Institute and the San Francisco International Wine and Spirits Competition. Drinks Americas was founded in 2004 by J. Patrick Kenny, a leading expert in beverage sales and marketing. Mr. Kenny developed his industry expertise in a variety of management positions at the world's leading beverage companies, including Joseph E. Seagram and Sons and The Coca-Cola Company. He has also acted as advisor to several Fortune 500 beverage marketing companies, and has participated in several beverage industry transactions.

About OTCPicks.com

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap and penny stocks. The web site features growing micro cap and penny stock companies. We publish a daily Free email newsletter highlighting the most active Pinksheets, OTCBB and penny stocks. To feature a company on our web site please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks.com has been compensated seven thousand five hundred dollars from company for this current MFLI advertising and promotional program. OTCPicks.com has been compensated four thousand dollars by a third party for XPGH advertising and promotional services.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.